Lv33
318 积分 2020-09-29 加入
Overcoming Resistance to Anti–Nectin-4 Antibody-Drug Conjugate
1小时前
已完结
Navigating the Landscape of Resistance Mechanisms in Antibody–Drug Conjugates for Cancer Treatment
1小时前
已完结
Cadonilimab combined with lenvatinib and transarterial chemoembolization for non-metastatic unresectable hepatocellular carcinoma: a multicenter, open-label, phase 2 study
2天前
已完结
Consensus on standardized later-line systemic therapy for hepatocellular carcinoma
14天前
已完结
Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 Study
27天前
已完结
Final Overall Survival and Molecular Analysis in IMmotion151, a Phase 3 Trial Comparing Atezolizumab Plus Bevacizumab vs Sunitinib in Patients With Previously Untreated Metastatic Renal Cell Carcinoma
27天前
已完结
First-line benmelstobart plus anlotinib versus sunitinib in advanced renal cell carcinoma (ETER100): a multicentre, randomised, open-label, phase 3 trial
27天前
已完结
Clinical toxicity of ADCs and ICI–ADC combinations: mechanisms, patterns and management
27天前
已完结
Observational registry of sorafenib use in clinical practice across Child-Pugh subgroups: The GIDEON study
1个月前
已完结
Systemic treatment in patients with hepatocellular carcinoma and advanced liver dysfunction
1个月前
已完结
皖公网安备34019202002308
